Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD

  • STATUS
    Recruiting
  • End date
    May 31, 2024
  • participants needed
    20
  • sponsor
    The First Affiliated Hospital of Soochow University
Updated on 8 December 2021

Summary

Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is one of the most important and effective methods for the treatment of hematologic malignancies.Chronic graft-versus-host disease (cGVHD) is a serious complication of allogeneic stem cell transplantation with few effective options available after failure of corticosteroids. It is a leading cause of late nonrelapse mortality for transplant patients, also contributing to morbidity and a decrease in quality of life.Corticosteroids, the standard frontline treatment, are typically administered for a median of 2 to 3 years, leading to substantial morbidity. An effort to decrease corticosteroid doses has led to their use in combination with other immunosuppressants, such as cyclosporine, tacrolimus, and sirolimus, in frontlineor second-line settings, despite a lack of clinical evidence supporting additional efficacy after combining these agents with corticosteroids. B and T cells play a rolein the pathophysiology of cGVHD. Previous studies have shown that low-dose histone deacetylase inhibitors (HDACi) have a negative immune regulation in GVHD while maintain the GVL effect. Chidamide is one of new HDACis in China, the previous studies suggested that low dose Chidamide could reduce condition of cGVHD mice by regulating the immune homeostasis of follicular helper T (Tfh) cells. Chidamide also has effects on the regulation of antigen presenting cells, the activation donor T cells, the release of proinflammatory cytokines and the function of Treg cells. Furthermore, low-dose Chidamide has the potential to maintain GVL effects. In preclinical models,Chidamide reduced severity of cGVHD. Based on the biological rationale and preclinical data, a study was designed to evaluate the safety and efficacy of Chidamide in patients with cGVHD who was steroid-resistant/steroid-dependent .

Description

Promoting graft-versus-leukemia (GVL) effect and inhibiting chronic graft-versus-host disease (cGVHD), is the key to improve the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Previous studies have shown that low-dose histone deacetylase inhibitors (HDACi) have a negative immune regulation in aGVHD while maintain the GVL effect. Chidamide is one of new HDACis in China, its immune regulatory role in cGVHD is unclear. The results suggested that low dose Chidamide could reduce condition of cGVHD mice by regulating the immune homeostasis of follicular helper T (Tfh) cells. Chidamide also has effects on the regulation of antigen presenting cells, the activation donor T cells, the release of proinflammatory cytokines and the function of Treg cells. Furthermore, low-dose Chidamide has the potential to maintain GVL effects.

On this basis,a study was designed to evaluate the safety and efficacy of Chidamide in patients with cGVHD who was steroid-resistant/steroid-dependent.To Evaluate the Safety and Tolerability of Chidamide in Steroid Dependent/Refractory cGVHD.Number of participants with dose-limiting toxicities as a measure of safety profile to determine recommended dose of Chidamide.

Inclusion Criteria:

  1. The disease progressed after at least 1 week of treatment with 1 mg/kg/d prednisone based immunosuppressive therapy;
  2. The disease did not improve after at least 1 month of immunosuppressive therapy with 1 mgkg once every 2 days or 0.5 mg/kg/d prednisone;
  3. Gocorticoid dependence: Prednisone with > 0.25 mg/kg/d or > 0.5 mgkg every 2 days after at least 8 weeks of glucocorticoid-based immunosuppressant therapy is required to prevent recurrence or progression.
  4. Patients with severe glucocorticoid-resistant/dependent cGVHD who have poor response to second-line treatment drugs (mycophoranate, high-dose glucocorticoid, extracorporeal light therapy, sirolimus, imatinib, azathiopurine, thalidomide, rituximab, anti-CD25, etc.).
  5. Ages 18-59
  6. ECOG score 0-3
  7. Expected survival longer than 6 months
  8. The patient who signed the informed consent must be able to understand and willing to participate in the study, and must sign the informed consent.

Exclusion Criteria:

  1. Basic diseases of important organs: such as myocardial infarction, chronic cardiac insufficiency, decompensated liver insufficiency, renal insufficiency, etc.;Clinically uncontrolled active infections (including bacterial, fungal or viral infections), but not those under effective medication;
  2. Malignant tumors with other progression;
  3. Cardiac dysfunction patients: ejection fraction (EF) < 30%, NYHA standard, cardiac dysfunction grade or above;
  4. Pregnant or lactating women;
  5. People undergoing clinical trials of other drugs; After screening according to inclusion and exclusion criteria, patients meeting the criteria were enrolled. Treatment regimen: Chidamide 15mg biw po, lasted for 8 weeks. Pretransplant use of Chidamide for reasons other than cGVHD, such as for the treatment of leukemia or lymphoma, was permitted.All patients received systemic corticosteroid therapy for cGVHD prior to and during the study; concomitant use of other immunosuppressive therapies was also permitted, however, pre-existing corticosteroid and immunosuppressant doses must have been stable for 14 days before initiating Chidamide. Doses of concomitant corticosteroids and immunosuppressants could be tapered during the study as clinically indicated.

Details
Condition Safety and Efficacy
Treatment Chidamide
Clinical Study IdentifierNCT05140616
SponsorThe First Affiliated Hospital of Soochow University
Last Modified on8 December 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

The disease progressed after at least 1 week of treatment with 1 mg/kg/d prednisone based immunosuppressive therapy
The disease did not improve after at least 1 month of immunosuppressive therapy with 1 mgkg once every 2 days or 0.5 mg/kg/d prednisone
Gocorticoid dependence: Prednisone with > 0.25 mg/kg/d or > 0.5 mgkg every 2 days after at least 8 weeks of glucocorticoid-based immunosuppressant therapy is required to prevent recurrence or progression
Patients with severe glucocorticoid-resistant/dependent cGVHD who have poor response to second-line treatment drugs (mycophoranate, high-dose glucocorticoid, extracorporeal light therapy, sirolimus, imatinib, azathiopurine, thalidomide, rituximab, anti-CD25, etc.)
Ages 18-59
ECOG score 0-3
Expected survival longer than 6 months
The patient who signed the informed consent must be able to understand and willing to participate in the study, and must sign the informed consent

Exclusion Criteria

Basic diseases of important organs: such as myocardial infarction, chronic cardiac insufficiency, decompensated liver insufficiency, renal insufficiency, etc.;Clinically uncontrolled active infections (including bacterial, fungal or viral infections), but not those under effective medication
Malignant tumors with other progression
Cardiac dysfunction patients: ejection fraction (EF) < 30%, NYHA standard, cardiac dysfunction grade or above
Pregnant or lactating women
People undergoing clinical trials of other drugs
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note